SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Anuh Pharma - Quaterly Results

07 Feb 2025 Evaluate
A decrease in the sales to Rs. 1595.13 millions was observed for the quarter ended December 2024. The sales stood at Rs. 1721.01 millions during the similar quarter previous year.A big decline of -45.88% was reported for the quarter ended December 2024 to Rs. 103.44  millions from Rs. 191.12 millions of corresponding previous quarter.A decline of 157.27 millions was observed in the OP in the quarter ended December 2024 from 276.49 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 1595.13 1721.01 -7.31 4633.75 4831.14 -4.09 6470.04 5274.86 22.66
Other Income 9.38 36.57 -74.35 80.57 92.76 -13.14 120.98 61.15 97.84
PBIDT 157.27 276.49 -43.12 502.94 652.02 -22.86 872.47 573.90 52.02
Interest 2.80 1.42 97.18 5.86 2.52 132.54 3.54 2.18 62.39
PBDT 154.47 275.07 -43.84 497.08 649.50 -23.47 868.93 571.72 51.99
Depreciation 21.81 22.02 -0.95 59.83 63.57 -5.88 85.84 97.00 -11.51
PBT 132.66 253.05 -47.58 437.25 585.93 -25.38 783.09 474.72 64.96
TAX 29.22 61.93 -52.82 88.30 138.94 -36.45 182.52 112.91 61.65
Deferred Tax -2.58 6.43 -140.12 -10.60 5.84 -281.51 3.59 -8.29 -143.31
PAT 103.44 191.12 -45.88 348.95 446.99 -21.93 600.57 361.81 65.99
Equity 250.56 250.56 0.00 250.56 250.56 0.00 250.56 250.56 0.00
PBIDTM(%) 9.86 16.07 -38.63 10.85 13.50 -19.58 13.48 10.88 23.94

Anuh Pharma Share Price

82.80 0.08 (0.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×